Osmotic Release Metformin Guideline Summary

Introduction to Osmotic Release Metformin

• Osmotic release metformin is a once-daily formulation of metformin that uses an osmotic tablet technology to provide controlled, gradual release of metformin over time, offering improved gastrointestinal tolerability while maintaining equivalent glycemic efficacy compared to immediate-release formulations 1

Dosing and Administration

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend starting with 500 mg once daily, increasing by 500 mg every 7 days until maximum dose or glycemic targets are achieved, with renal dosing adjustments based on eGFR levels 1
• For patients with type 2 diabetes and CKD with eGFR ≥30 mL/min/1.73m², metformin is recommended as first-line therapy 1

Monitoring and Side Effects

• Monitoring should include renal function, with eGFR checked at least annually, or every 3-6 months if eGFR <60 mL/min/1.73m², as well as periodic checks of vitamin B12 levels in patients taking metformin for more than 4 years 1, 2
• Long-term use of metformin may lead to decreased vitamin B12 levels, and patients should be monitored for vitamin B12 deficiency 1, 2

Treatment Recommendations

• The American Diabetes Association recommends metformin (including extended-release) as the preferred initial pharmacologic agent for type 2 diabetes, to be continued as long as tolerated and not contraindicated 3, 4, 5
• For patients requiring additional glycemic control, GLP-1 receptor agonists are generally preferred as add-on therapy 1